quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:47:42·84d
PRRelease
Protalix BioTherapeutics Inc. (DE) logo

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

PLX· Protalix BioTherapeutics Inc. (DE)
Health Care
Original source

Companies

  • PLX
    Protalix BioTherapeutics Inc. (DE)
    Health Care

Related

  • SEC37d
    SEC Form 10-K filed by Protalix BioTherapeutics Inc. (DE)
  • SEC37d
    Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR37d
    Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
  • PR44d
    Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
  • PR46d
    Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
  • SEC46d
    Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR46d
    Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
  • PR50d
    Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022